Genome & Company (KOSDAQ:314130)

Genome & Company Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 8, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	230,992	238,384	85,207	176,209	245,897	468,827
Market Cap Growth	207.06%	179.77%	-51.64%	-28.34%	-47.55%	-55.28%
Enterprise Value	226,623	227,511	89,070	151,242	185,907	383,841
Last Close Price	6620.00	6880.00	2750.00	6245.00	8725.00	17350.00
PS Ratio	9.39	9.70	3.07	12.33	17.46	1038.96
PB Ratio	2.02	2.08	0.86	1.55	1.63	4.13
P/TBV Ratio	2.74	2.83	3.40	4.83	3.73	8.10
EV/Sales Ratio	9.22	9.25	3.21	10.58	13.20	850.63
Debt / Equity Ratio	0.17	0.17	0.32	0.23	0.04	0.06
Net Debt / Equity Ratio	-0.16	-0.16	-0.49	-0.53	-0.67	-0.62
Net Debt / EBITDA Ratio	0.79	0.79	2.92	1.28	2.09	2.10
Net Debt / FCF Ratio	0.96	0.96	2.41	1.17	1.99	2.42
Asset Turnover	0.17	0.17	0.18	0.09	0.09	0.00
Inventory Turnover	1.90	1.90	2.59	3.53	4.76	-
Quick Ratio	1.90	1.90	2.80	3.09	9.83	8.03
Current Ratio	2.31	2.31	3.08	3.36	10.49	8.32
Return on Equity (ROE)	-7.20%	-7.20%	-25.26%	-38.36%	-43.15%	-31.51%
Return on Assets (ROA)	-12.50%	-12.50%	-9.78%	-20.55%	-23.17%	-17.48%
Return on Capital Employed (ROCE)	-23.90%	-23.90%	-20.60%	-41.40%	-35.50%	-28.30%
Earnings Yield	-2.78%	-2.70%	-23.60%	-26.94%	-21.08%	-7.28%
FCF Yield	-8.08%	-7.83%	-23.82%	-28.99%	-20.50%	-6.19%
Buyback Yield / Dilution	-2.90%	-2.90%	-7.91%	-0.32%	-4.71%	-39.60%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.